RU2350333C3 - Применение ивермектина для лечения дерматологических расстройств - Google Patents

Применение ивермектина для лечения дерматологических расстройств

Info

Publication number
RU2350333C3
RU2350333C3 RU2005136438A RU2005136438A RU2350333C3 RU 2350333 C3 RU2350333 C3 RU 2350333C3 RU 2005136438 A RU2005136438 A RU 2005136438A RU 2005136438 A RU2005136438 A RU 2005136438A RU 2350333 C3 RU2350333 C3 RU 2350333C3
Authority
RU
Russia
Prior art keywords
treatment
ivermectin
application
dermatologic disorders
composition
Prior art date
Application number
RU2005136438A
Other languages
English (en)
Other versions
RU2005136438A (ru
RU2350333C2 (ru
Original Assignee
Галдерма С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33312271&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2350333(C3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR0305048A external-priority patent/FR2854074B1/fr
Application filed by Галдерма С.А. filed Critical Галдерма С.А.
Publication of RU2005136438A publication Critical patent/RU2005136438A/ru
Application granted granted Critical
Publication of RU2350333C2 publication Critical patent/RU2350333C2/ru
Publication of RU2350333C3 publication Critical patent/RU2350333C3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Claims (8)

1. Применение ивермектина для получения фармацевтической композиции для топического нанесения, предназначенной для лечения розовых угрей, включающей:
Figure 00000001
воду qs до 100%,
в масс.% по отношению к общей массе композиции.
2. Композиция для топического нанесения, предназначенная для использования человеком, содержащая:
Figure 00000002
в масс.% по отношению к общей массе композиции.
3. Применение композиции по любому из пп. 1-2 для получения лекарственного средства, предназначенного для лечения розовых угрей.
RU2005136438A 2003-04-24 2004-04-22 Применение ивермектина для лечения дерматологических расстройств RU2350333C3 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0305048 2003-04-24
FR0305048A FR2854074B1 (fr) 2003-04-24 2003-04-24 Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
US46899403P 2003-05-09 2003-05-09
US60/468,994 2003-05-09

Publications (3)

Publication Number Publication Date
RU2005136438A RU2005136438A (ru) 2006-05-27
RU2350333C2 RU2350333C2 (ru) 2009-03-27
RU2350333C3 true RU2350333C3 (ru) 2018-08-24

Family

ID=33312271

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005136438A RU2350333C3 (ru) 2003-04-24 2004-04-22 Применение ивермектина для лечения дерматологических расстройств

Country Status (15)

Country Link
US (6) US7550440B2 (ru)
EP (1) EP1620113B1 (ru)
JP (2) JP5711867B2 (ru)
KR (1) KR101187231B1 (ru)
AU (1) AU2004231323C1 (ru)
BR (1) BRPI0410503B8 (ru)
CA (1) CA2522579C (ru)
CY (2) CY1111797T1 (ru)
HU (1) HUS1500048I1 (ru)
LT (1) LTC1620113I2 (ru)
LU (1) LU92915I2 (ru)
MX (1) MXPA05011208A (ru)
PL (2) PL378932A1 (ru)
RU (1) RU2350333C3 (ru)
WO (1) WO2004093886A1 (ru)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2854074B1 (fr) 2003-04-24 2007-11-23 Galderma Res & Dev Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
KR101187231B1 (ko) * 2003-04-24 2012-10-02 갈데르마 소시에떼아노님 피부과 질병 치료용 이버멕틴의 외용 제형물
BR0318319A (pt) * 2003-05-25 2006-07-18 Yuwan Wang métodos de preparação e formulações/composições sustentadas pelo uso de dimeticona como veìculo
DE602005020912D1 (de) 2004-03-18 2010-06-10 Galderma Sa Ivermectin enthaltende creme
FR2867684B1 (fr) * 2004-03-18 2006-05-05 Galderma Sa Gel creme contenant de l'ivermectine
FR2883181B1 (fr) * 2005-03-17 2007-05-18 Galderma Sa Composition a base d'une avermectine et d'acide azelaique notamment pour le traitement de la rosacee
FR2886851B1 (fr) * 2005-06-10 2007-10-05 Galderma Sa Composition a base d'une avermectine et de metronidazole notamment pour le traitement de la rosacee
FR2886850B1 (fr) * 2005-06-10 2007-10-05 Galderma Sa Composition a base d'une avermectine et de peroxyde de benzoyle notamment pour le traitement de la rosacee
FR2886852B1 (fr) * 2005-06-10 2007-11-23 Galderma Sa Composition a base d'une avermectine et d'hydrocortisone notamment pour le traitement de la rosacee
FR2894823B1 (fr) * 2005-12-20 2008-02-29 Galderma Sa Composition de type emulsion inverse comprenant de l'ivermectine, et ses utilisations en cosmetique et en dermatologie
FR2900052B1 (fr) * 2006-04-19 2011-02-18 Galderma Sa Composition comprenant au moins une phase aqueuse et au moins une phase grasse comprenant de l'ivermectine
FR2906468B1 (fr) * 2006-09-28 2012-09-21 Galderma Sa Utilisation de composes de la famille des avermectines pour le traitement de desordres dermatologiques
FR2907012B1 (fr) 2006-10-12 2012-09-21 Galderma Sa Composition dermatologique comprenant des nanocapsules d'avermectine, son procede de preparation et son utilisation
FR2907013B1 (fr) * 2006-10-12 2012-09-21 Galderma Sa Produits de soin cutane a double compartiment comprenant de l'ivermectine, et leurs utilisations
ES2653259T3 (es) 2006-10-12 2018-02-06 Topaz Pharmaceuticals Inc. Formulaciones tópicas de ivermectina y procedimientos de eliminación y profiláxis de piojos del cuerpo
US8901163B2 (en) * 2007-01-03 2014-12-02 Galderma S.A. Method of treating hyperesthesia, paresthesia, dolor, and pruritus caused by insect stings or noxious weeds or plants using avermectin compound
DE102007056424A1 (de) * 2007-11-23 2009-05-28 Neopharmacie Gmbh Pharmazeutische Zusammensetzung, enthaltend eine Öl/Wasser-Emulsion
MX2011004442A (es) * 2008-10-29 2011-10-14 Topaz Pharmaceuticals Inc Sistema conservante para formulaciones topicas terapeuticas basadas en emulsion.
US20120004200A1 (en) * 2008-12-23 2012-01-05 Galderma S.A. Topical pharmaceutical composition containing a water-sensitive active principle
US8642665B2 (en) 2011-12-16 2014-02-04 Conopco, Inc. Environmentally friendly, low whitening compositions
JP5717034B2 (ja) * 2012-08-27 2015-05-13 丸和バイオケミカル株式会社 マクロライド系化合物を含有する土壌線虫防除用薬剤
FR3000397A1 (fr) * 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et d'ivermectine pour le traitement de la rosacee
CN103356687B (zh) 2012-10-19 2016-06-01 厦门大学 一种伊维菌素及其衍生物的用途
FR3003761B1 (fr) * 2013-03-29 2016-01-01 Galderma Sa Utilisation d'une lactone macrocyclique pour le traitement d'une infection par un papillomavirus
US9233117B2 (en) 2013-07-08 2016-01-12 Galderma S. A. Treatment of inflammatory lesions of rosacea with ivermectin
US9782425B2 (en) 2013-07-08 2017-10-10 Galderma S.A. Treatment of papulopustular rosacea with ivermectin
BR112016002387B1 (pt) 2013-08-08 2019-05-21 Novan, Inc. Composições farmacêuticas tópicas, e método para seu armazenamento
WO2015079016A1 (en) 2013-11-29 2015-06-04 Galderma Sa Compound of the avermectin family or of the milbemycin family for the treatment and/or prevention of atopic dermatitis
CN104706584A (zh) * 2013-12-16 2015-06-17 天津迈迪瑞康生物医药科技有限公司 一种伊维菌素脂肪乳浓缩液、其制备方法及用途
US10322082B2 (en) 2014-07-11 2019-06-18 Novan, Inc. Topical antiviral compositions and methods of using the same
US20170232024A1 (en) * 2014-08-04 2017-08-17 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
FR3026010B1 (fr) * 2014-09-18 2016-11-04 Galderma Sa Compositions comprenant un compose de la famille des avermectines et de la doxycycline pour le traitement de la rosacee
WO2016096795A1 (en) * 2014-12-15 2016-06-23 Galderma Sa Compound of the avermectin family for treating and/or preventing inflammatory dermatoses
WO2016096797A1 (en) 2014-12-15 2016-06-23 Galderma Sa Compound of the avermectin family in combination with an other active compound for treating and/or preventing inflammatory dermatoses
WO2017064206A1 (en) 2015-10-13 2017-04-20 Galderma Sa A process for preparing a composition comprising a high concentration of one or more avermectins
CN108136029B (zh) * 2015-10-13 2020-12-25 盖尔德玛公司 包含一种或多种阿维菌素的稳定乳液的制备方法
JP2019523291A (ja) 2016-08-04 2019-08-22 ネスレ スキン ヘルス エス アー 酒さを治療又は予防するための組成物及びその使用
US11160780B2 (en) * 2016-09-30 2021-11-02 Aurobindo Pharma Ltd. Pharmaceutical composition of ivermectin and process for preparation thereof
WO2018083196A1 (en) 2016-11-03 2018-05-11 Nestlé Skin Health Sa Compositions comprising a compound of the avermectin family for the treatment and/or prevention of hand eczema
EP3326609A1 (en) 2016-11-24 2018-05-30 Nestlé Skin Health SA Composition comprising avermectin compounds without gelling agents
EP3326608A1 (en) 2016-11-24 2018-05-30 Nestlé Skin Health SA Composition comprising avermectin compounds without solid fatty substances
EP3326614A1 (en) 2016-11-24 2018-05-30 Nestlé Skin Health SA Composition comprising avermectin compounds without solvents and propenetrating agents of avermectin compounds
EP3638251B1 (en) * 2017-06-12 2024-03-06 Lakewood Amedex, Inc. Bisphosphocin gel formulations and uses thereof
IL307992A (en) 2017-12-15 2023-12-01 Tarsus Pharmaceuticals Inc Parasitic formulations containing isoxazoline and methods for treating blepharitis
SG11202102783QA (en) * 2018-09-28 2021-04-29 Galderma Res & Dev Pharmaceutical composition in the form of a water-in-oil emulsion (w/o) and its uses
US11312922B2 (en) 2019-04-12 2022-04-26 Ecolab Usa Inc. Antimicrobial multi-purpose cleaner comprising a sulfonic acid-containing surfactant and methods of making and using the same
CA3148675A1 (en) * 2019-08-21 2021-02-25 Kin F. Chan Solvent delivery system for topical delivery of active agents
KR102480430B1 (ko) 2020-10-21 2022-12-21 순천향대학교 산학협력단 주사증 진단을 위한 마이크로RNA-31-5p 및 이의 용도
KR20220052474A (ko) 2020-10-21 2022-04-28 순천향대학교 산학협력단 주사증 진단을 위한 마이크로RNA-21-3p 및 이의 용도
US11291679B1 (en) * 2021-03-22 2022-04-05 Mountain Valley Md Inc. Injectable, infusable, instillable ivermectin adjuvant for cancer therapies
EP4062907A1 (fr) 2021-03-23 2022-09-28 Substipharm Formulation par voie orale d'ivermectine et utilisations

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5332577A (en) * 1988-12-27 1994-07-26 Dermamed Transdermal administration to humans and animals
US5952371A (en) * 1996-10-16 1999-09-14 Merck & Co., Inc. Triterpene derivatives with immunosuppressant activity
US5952372A (en) * 1998-09-17 1999-09-14 Mcdaniel; William Robert Method for treating rosacea using oral or topical ivermectin
US6310968B1 (en) * 1998-11-24 2001-10-30 Picker International, Inc. Source-assisted attenuation correction for emission computed tomography
AU781703B2 (en) * 1999-01-25 2005-06-09 Blue Ridge Pharmaceuticals, Inc. Liposome formulations
US6133310A (en) * 1999-08-26 2000-10-17 Parks; L. Dean Method of treatment of rosacea
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6399652B1 (en) 2000-06-29 2002-06-04 L. Dean Parks Method of treating acne vulgaris using avermectin compound
US6319945B1 (en) * 2000-06-29 2001-11-20 L. Dean Parks Method of treatment of seborrheic dermatitis
US6399651B1 (en) * 2000-06-29 2002-06-04 L. Dean Parks Method of treating dermatoses using avermectin compound
DE10063946A1 (de) * 2000-12-20 2002-07-04 Basf Ag Verwendung von Lichtschutzmittelkombinationen, die als wesentlichen Bestandteil 2,2'-p-Phenylen-bis(3,1-benzoxazin-4-on) enthalten als photostabile UV-Filter in kosmetischen und pharmazeutischen Zubereitungen
EP1476121A4 (en) * 2002-02-08 2010-10-27 Merck Sharp & Dohme TOPICAL IVERMECTIN COMPOSITION
WO2003075656A2 (en) * 2002-03-04 2003-09-18 Divergence, Inc. Nematicidal fatty acid and fatty acid ester related compounds
KR101187231B1 (ko) * 2003-04-24 2012-10-02 갈데르마 소시에떼아노님 피부과 질병 치료용 이버멕틴의 외용 제형물
DE602005020912D1 (de) * 2004-03-18 2010-06-10 Galderma Sa Ivermectin enthaltende creme
FR2867684B1 (fr) 2004-03-18 2006-05-05 Galderma Sa Gel creme contenant de l'ivermectine

Also Published As

Publication number Publication date
HUS1500048I1 (hu) 2017-10-30
JP2006524212A (ja) 2006-10-26
EP1620113B1 (en) 2011-07-13
CY1111797T1 (el) 2015-10-07
US8415311B2 (en) 2013-04-09
CY2016031I1 (el) 2017-03-15
JP2012126738A (ja) 2012-07-05
US20130209381A1 (en) 2013-08-15
KR20060004667A (ko) 2006-01-12
AU2004231323B2 (en) 2009-12-10
US8093219B2 (en) 2012-01-10
AU2004231323A1 (en) 2004-11-04
US20120077766A1 (en) 2012-03-29
RU2005136438A (ru) 2006-05-27
US8598129B2 (en) 2013-12-03
PL1620113T3 (pl) 2011-10-31
BRPI0410503B8 (pt) 2021-05-25
LTC1620113I2 (lt) 2018-02-26
US7550440B2 (en) 2009-06-23
US20060100165A1 (en) 2006-05-11
PL378932A1 (pl) 2006-06-12
EP1620113A1 (en) 2006-02-01
CA2522579C (en) 2012-08-28
CY2016031I2 (el) 2017-03-15
US20090227668A1 (en) 2009-09-10
CA2522579A1 (en) 2004-11-04
RU2350333C2 (ru) 2009-03-27
KR101187231B1 (ko) 2012-10-02
WO2004093886A1 (en) 2004-11-04
JP5538461B2 (ja) 2014-07-02
US20090252797A1 (en) 2009-10-08
LU92915I2 (fr) 2016-02-17
JP5711867B2 (ja) 2015-05-07
BRPI0410503A (pt) 2006-06-20
US8080530B2 (en) 2011-12-20
BRPI0410503B1 (pt) 2018-07-10
US8470788B2 (en) 2013-06-25
MXPA05011208A (es) 2005-12-14
AU2004231323C1 (en) 2016-11-03
US20120258062A1 (en) 2012-10-11

Similar Documents

Publication Publication Date Title
RU2350333C3 (ru) Применение ивермектина для лечения дерматологических расстройств
FR2889811B1 (fr) Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.
BRPI0309544B8 (pt) preparação farmacêutica oral estável ao armazenamento compreendendo oxicodona e naloxona
CL2007001918A1 (es) Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras.
BR0113663A (pt) Composições de pelìcula de pectina
EA200600484A1 (ru) Доставка физиологических агентов in situ при помощи гелей, включающих анионные полисахариды
FR2866884B1 (fr) Derives d'aryl-et d'heteroaryl-piperidinecarboxylates, leur preparation et leur application en therapeutique
FR2867684B1 (fr) Gel creme contenant de l'ivermectine
IL167250A (en) Chirale oxazole-arylpropionic acid derivatives, compositions comprising thereof and their use in the preparation of medicaments for the treatment of ppar alpha/ ppar gamma agonists-modulated diseases
JP2005507892A5 (ru)
DE60336225D1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
DE60103512D1 (de) Pharmazeutische zusammensetzung enthaltend pemetrexed zusammen mit monothioglycerol, l-cystein oder thioglykolsäure
ITMI20031396A1 (it) Composizione per uso farmaceutico o dietetico o cosmetico dotata di attivita' antiossidante.
FR2873690B1 (fr) Derives d'oxopiperidine, leur preparation et leur application en therapeutique
HK1097762A1 (en) Pharmaceutical compositions for the treatment of renal dysfunction, disease or disorder, in particular in diabetic patients
EA200702496A1 (ru) Местная композиция, содержащая желатин
DE602004030564D1 (de) 2-substituierte phenyl-5,7-dialkyl-3,7-dihydropyrrolä2,3-dü pyrimidin-4-onderivate, deren herstellung und pharmazeutische verwendung
BRPI0418764B8 (pt) uso de espinosina, ou de um derivado ou sal fisiologicamente aceitável da mesma, na preparação de medicamentos para promover ou acelerar a cura de ferimento em um ser humano
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
FR2873693B1 (fr) Derives d'amino-tropane, leur preparation et leur application en therapeutique
ITMI20021866A1 (it) Preparazione farmaceutica in forma colloidale utile nella cura delle affezioni cutanee.
FR2842527B1 (fr) Derives d'acyloxypyrolidine, leur preparation et leur application en therapeutique
FR2866886B1 (fr) Derives d'aryl-et d'heteroaryl-akylcarbamates, leur preparation et leur application en therapeutique
JP2010521519A5 (ru)
JP2004224775A5 (ru)

Legal Events

Date Code Title Description
ND4A Extension of patent duration

Effective date: 20180824